Amphetamine (AMP) Rapid Test Device

Amphetamine, commonly abbreviated as AMP in drug testing, is a stimulant compound that affects brain and nervous system activity. It is associated with increased activity of neurotransmitters such as dopamine and norepinephrine. In some medical systems, amphetamine-based medicines may be used under prescription control, but misuse may lead to dependency, health risks, and safety concerns. The Amphetamine (AMP) Rapid Test Device is designed to support professional screening for amphetamine in urine specimens.

The Amphetamine (AMP) Rapid Test Device is used for preliminary qualitative screening of amphetamine in urine. It is not designed to diagnose addiction, overdose, intoxication, or any medical condition by itself. Instead, it supports professional screening programs where rapid preliminary information is required.

Applications

• Clinical laboratory urine screening
• Hospital toxicology support
• Emergency care screening workflows
• Rehabilitation and de-addiction centers
• Occupational health screening programs
• Forensic screening facilities
• Institutional drug monitoring workflows
• Professional diagnostic and compliance testing programs

• Urine testing is commonly used in toxicology because it provides a practical specimen type for drug screening workflows. The Amphetamine rapid test urine format helps professionals screen urine specimens quickly at the stated 1000 ng/mL cut-off.
• Immunoassay-based drug screening is useful for rapid preliminary testing, but it may produce presumptive results. Positive screening results may require confirmatory testing using validated laboratory methods such as GC-MS or LC-MS/MS, especially when results may affect medical, workplace, forensic, or institutional decisions.
• The Amphetamine (AMP) Rapid Test Device by LARKSOIS Pharma is intended to support responsible screening and reporting systems in controlled professional environments.

The Amphetamine (AMP) Rapid Test Device uses a rapid urine test format for qualitative screening of amphetamine. The device is designed to provide a preliminary result at the stated 1000 ng/mL cut-off.

Benefits

• Urine-based rapid screening format
• 1000 ng/mL cut-off level
• Designed for amphetamine / AMP detection
• Supports toxicology and drug monitoring workflows
• Suitable for professional laboratory use
• Fast preliminary screening support
• Useful for hospitals, rehabilitation centers, and occupational programs
• Designed for international healthcare and diagnostic markets

The Amphetamine (AMP) Rapid Test Device is designed for urine specimens. Urine is widely used in drug screening because it is practical for detecting drug exposure in professional screening workflows.

Guidance

• Use urine specimens only
• Use clean sample collection procedures
• Follow the product insert carefully
• Treat all urine samples as potentially biohazardous
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, legal, workplace, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Amphetamine (AMP) Rapid Test Device by LARKSOIS Pharma has a stated cut-off of 1000 ng/mL. This means the device is designed to screen for amphetamine in urine at or above the validated threshold. LARKSOIS Pharma should mention the exact cut-off and performance details according to the final product insert, technical file, and regulatory documentation.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Amphetamine (AMP) Rapid Test Device.

Positive

A positive result suggests that amphetamine may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary unless confirmed by an appropriate laboratory method.

Negative

A negative result suggests that amphetamine was not detected or was below the test cut-off at the time of testing. A negative result does not replace clinical or professional judgment.

Invalid

If the control indicator does not appear, the result is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store according to the product label and package insert
• Protect from moisture, direct sunlight, high temperature, and contamination
• Do not use expired test devices
• Do not use damaged or opened pouches
• Keep sealed until use
• Interpret results within the stated reading window
• Dispose of used materials according to laboratory safety rules

Instructions

• For professional in vitro diagnostic use only
• Not intended for home use
• Not intended to diagnose addiction, overdose, or intoxication
• Not a substitute for clinical evaluation
• Positive results are preliminary unless confirmed
• Negative results do not replace professional judgment
• Use confirmatory testing where clinical, legal, forensic, workplace, or institutional decisions require it
• Always follow local laboratory, occupational, forensic, and regulatory guidelines

LARKSOIS Pharma focuses on reliable diagnostic solutions for global healthcare providers, laboratories, distributors, and institutional screening programs. The Amphetamine (AMP) Rapid Test Device is developed for professional environments where speed, clarity, and dependable screening support are important.

Advantages

• Urine-based rapid screening format
• 1000 ng/mL cut-off level
• Supports toxicology and drug monitoring workflows
• Suitable for professional laboratory use
• Fast preliminary screening support
• Useful for hospitals, rehabilitation centers, and occupational programs
• Designed for international healthcare markets
• Helps support responsible screening and reporting systems